Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002509 · ClinicalTrials.gov registry record · Phase 1
High-Dose Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Poor-Prognosis Breast Cancer
A Phase 1 study, sponsored by Temple University.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00002509: Completed Phase 1 study, sponsored by Temple University.
NCT00002509 is a Phase 1 study that has completed, run by Temple University. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002509, a Phase 1 study, has completed, sponsored by Temple University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining peripheral stem cell transplantation with combinations of drugs may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of high-dose combination chemotherapy followed by peripheral stem cell transplantation or autologous bone marrow transplantation in women with stage II breast cancer with eight or more positive axillary lymph nodes and in women with stage III or metastatic breast cancer.
Interventions
- DRUG carboplatin
- DRUG cyclophosphamide
- DRUG etoposide
- BIOLOGICAL filgrastim
- DRUG mesna
Trial Details
| Field | Value |
|---|---|
| Start Date | 1991-11 |
| Est. Completion | 2003-12 |
| Phase | Phase 1 |
What the finished NCT00002509 record still lists
NCT00002509 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 5 interventions - of which carboplatin is the first listed.
NCT00002509 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002509 about?
NCT00002509 is a clinical study titled "High-Dose Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Poor-Prognosis Breast Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining peripheral stem cell transplantation with combinations of drugs may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of high-dose combination ...
What is the current status of trial NCT00002509?
This trial is currently completed. It is a Phase 1 study. The study started on 1991-11. Estimated completion is 2003-12.
What interventions are being tested in trial NCT00002509?
The interventions under investigation include: carboplatin (DRUG), cyclophosphamide (DRUG), etoposide (DRUG), filgrastim (BIOLOGICAL), mesna (DRUG).
Who is sponsoring clinical trial NCT00002509?
This trial is sponsored by Temple University, which has 163 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia